Open AccessComparison of the FDA-Approved CDC DENV-1-4 Real-Time Reverse Transcription-PCR with a Laboratory-Developed Assay for Dengue Virus Detection and Serotyping
Author(s) -
Jesse J. Waggoner,
Janaki Abeynayake,
Malaya K. Sahoo,
Lionel Gresh,
Yolanda Téllez,
Karla González,
Gabriela Ballesteros,
Frances P. Guo,
Ángel Balmaseda,
Kumudu Karunaratne,
Eva Harris,
Benjamin A. Pinsky
Publication year - 2013
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.01359-13
Subject(s) - dengue virus , virology , serotype , dengue fever , multiplex , reverse transcription polymerase chain reaction , biology , reverse transcriptase , real time polymerase chain reaction , virus , polymerase chain reaction , bioinformatics , gene , gene expression , biochemistry
Dengue virus (DENV) is the agent of the most common vector-borne disease worldwide. Using 199 clinical samples collected from Nicaragua and Sri Lanka, a laboratory-developed DENV multiplex real-time reverse transcription-PCR (rRT-PCR) proved more clinically sensitive than the FDA-approved CDC assay for DENV serotypes 1 to 4 when measured against a composite reference standard, with sensitivities of 97.4% versus 87.1%, respectively.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom